Literature DB >> 11107115

Role of survivin, whose gene is mapped to 17q25, in human neuroblastoma and identification of a novel dominant-negative isoform, survivin-beta/2B.

A Islam1, H Kageyama, K Hashizume, Y Kaneko, A Nakagawara.   

Abstract

PROCEDURE: We investigated the expression of survivin (SVV) and its isoform (SVV-beta/2B) during different biological properties in neuroblastoma (NBL).
RESULTS: High levels of SVV mRNA expression were significantly associated with advanced stages of NBL, diagnosis at over 1 year of age, low levels of TrkA expression, and sporadic tumors. Expression of a novel isoform, SVV-beta/2B, which had an insertion of 23 amino acids within the unique BIR domain was predominant in some favorable NBLs, while it was low and ubiquitous in most normal and malignant tissues. The SVV expression wasdown-regulated during apoptosis induced by retinoic acid (RA) in CHP134 NBL cells, which was inhibited by forced expression of SVV. In contrast, SVV-beta was constantly expressed during apoptosis. Like SVV,SVV-beta was also highly expressed during G(2)/M in a cell cycle-dependent manner, and was associated with but competed against SVV for binding with polymerized tubulin.
CONCLUSION: These data suggest that expression of SVV is a poor prognostic indicator in human NBL, and it promotes growth and survival by regulating the levels of both isoforms. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11107115     DOI: 10.1002/1096-911x(20001201)35:6<550::aid-mpo12>3.0.co;2-y

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  17 in total

1.  Survivin gene-expression and splicing isoforms in oral squamous cell carcinoma.

Authors:  Salvatore De Maria; Giuseppe Pannone; Pantaleo Bufo; Angela Santoro; Rosario Serpico; Salvatore Metafora; Corrado Rubini; Daniela Pasquali; Silvana M Papagerakis; Stefania Staibano; Gaetano De Rosa; Ernesto Farina; Monica Emanuelli; Andrea Santarelli; Maria Ada Mariggiò; Lucio Lo Russo; Lorenzo Lo Muzio
Journal:  J Cancer Res Clin Oncol       Date:  2008-07-19       Impact factor: 4.553

2.  Nuclear survivin expression predicts poorer prognosis in glioblastoma.

Authors:  Katsuyuki Shirai; Yoshiyuki Suzuki; Kuniyuki Oka; Shin-ei Noda; Hiroyuki Katoh; Yoshihiko Suzuki; Jun Itoh; Hideaki Itoh; Shogo Ishiuchi; Hideyuki Sakurai; Masatoshi Hasegawa; Takashi Nakano
Journal:  J Neurooncol       Date:  2008-10-25       Impact factor: 4.130

3.  Cellular localisation of survivin: impact on the prognosis in colorectal cancer.

Authors:  T Ponnelle; C Chapusot; L Martin; A M Bouvier; S Plenchette; J Faivre; E Solary; F Piard
Journal:  J Cancer Res Clin Oncol       Date:  2005-05-18       Impact factor: 4.553

4.  Expression of survivin and its four splice variants in colorectal cancer and its clinical significances.

Authors:  Quan-Xing Ge; Yu-Yuan Li; Yu-Qiang Nie; Wen-Ge Zuo; Yan-Lei Du
Journal:  Med Oncol       Date:  2013-03-15       Impact factor: 3.064

5.  Influence of survivin and caspase-3 on cell apoptosis and prognosis in gastric carcinoma.

Authors:  Yun-Hong Li; Chen Wang; Kui Meng; Long-Bang Chen; Xiao-Jun Zhou
Journal:  World J Gastroenterol       Date:  2004-07-01       Impact factor: 5.742

6.  Forced expression of survivin-2B abrogates mitotic cells and induces mitochondria-dependent apoptosis by blockade of tubulin polymerization and modulation of Bcl-2, Bax, and survivin.

Authors:  Xiang Ling; Qiuying Cheng; Jennifer D Black; Fengzhi Li
Journal:  J Biol Chem       Date:  2007-07-25       Impact factor: 5.157

7.  Change in Expression of Survivin Caused by Using Oxaliplatin in HCT116 Colon Cancer Cells.

Authors:  Won Jun Sohn; Jung Won Lee; Dong-Guk Park
Journal:  J Korean Soc Coloproctol       Date:  2010-08-31

8.  Expression of the survivin-2B splice variant related to the progression of colorectal carcinoma.

Authors:  Gyu-Seok Cho; Tae Sung Ahn; Dongjun Jeong; Jae-Jun Kim; Chang-Jin Kim; Hyun-Deuk Cho; Dong-Kook Park; Moo-Jun Baek
Journal:  J Korean Surg Soc       Date:  2011-06-09

9.  Survivin, Survivin-2B, and Survivin-deItaEx3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcome.

Authors:  J R Fangusaro; Y Jiang; M P Holloway; H Caldas; V Singh; D R Boué; J Hayes; R A Altura
Journal:  Br J Cancer       Date:  2005-01-31       Impact factor: 7.640

10.  Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression.

Authors:  A Krieg; C Mahotka; T Krieg; H Grabsch; W Müller; S Takeno; C V Suschek; M Heydthausen; H E Gabbert; C D Gerharz
Journal:  Br J Cancer       Date:  2002-03-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.